US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
62 deals · US$14bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Feb 2026 | Sensei Biotherapeutics | – | – | Placement | Pending | 200.0 | Biotech+2 | Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager) |
| Feb 2026 | Liminatus Pharma | – | – | Follow-on offering | Announced | 4.0 | Biotech+2 | Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager) |
| Feb 2026 | Agomab Therapeutics NV | – | – | IPO | Announced | 200.0 | Biotech+2 | Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager) |
| Feb 2026 | Eikon Therapeutics | – | – | IPO | Announced | 381.2 | Oncology+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager) |
| Feb 2026 | Veradermics | – | – | IPO | Announced | 256.3 | Dermatology+2 | Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager) |
| Feb 2026 | Perspective Therapeutics | – | – | Follow-on offering | Announced | 175.0 | Radiopharmaceuticals+2 | Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager) |
| Jan 2026 | Polaryx Therapeutics | – | – | Direct listing | Completed | – | Biotech+1 | Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer) |
| Jan 2026 | Aktis Oncology | – | – | IPO | Listed | 317.7 | Biotech+2 | Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager) |
| Dec 2025 | Apimeds Pharmaceuticals US | – | – | Convertible | Completed | 10.9 | Pharma+1 | Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager) |
| – | Lakewood-Amedex Biotherapeutics | – | – | Direct listing | Announced | – | Biotech+1 | RBW Capital Partners (issuer) |
| – | Silexion Therapeutics Corp | – | – | Follow-on offering | Announced | 2.5 | Biotech+2 | Conyers (issuer)Greenberg Traurig (issuer)H.C. Wainwright & Co. (lead manager)Ellenoff Grossman & Schole (lead manager) |
| – | Vogenx | – | – | IPO | Announced | 81.3 | Biotech | Smith Anderson (issuer)JonesTrading (lead manager)Sichenzia Ross Ference Carmel (lead manager) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built